湿毒清制剂肝损伤风险分析及思考

doi:10.19803/j.1672-8629.20240137

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 666-670.
DOI: 10.19803/j.1672-8629.20240137

湿毒清制剂肝损伤风险分析及思考

邵波¹, 徐丽丽^2△, 朱兰¹, 刘硕¹, 万浩³, 黄光瑞⁴

¹国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076;
²中国中医科学院中医药信息研究所,北京100700;
³中国疾病预防控制中心,北京 102206;
⁴北京中医药大学生命科学学院,北京 100029

收稿日期:2024-02-29 出版日期:2024-06-15 发布日期:2024-06-18
作者简介:邵波,女,硕士,主治医师,中药上市后安全性研究。^△为并列第一作者。
基金资助:
中国中医科学院基本科研业务费优秀青年科技人才培养专项（传承类）（ZZ15-YQ-076）; 国家重点研发计划（2018YFC1707409）

Risks of liver injury caused by Shiduqing preparations

SHAO Bo¹, XU Lili^2△, ZHU Lan¹, LIU Shuo¹, WAN Hao³, HUANG Guangrui⁴

¹Center for Drug Reevaluation, NMPA/NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100076, China;
²Institute of Information on Tradition Chinese Medicine, Beijing 100700, China;
³Chinese Center for Disease Control and Prevention, Beijing 102206, China;
⁴School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China

Received:2024-02-29 Online:2024-06-15 Published:2024-06-18

摘要/Abstract

摘要： 目的分析湿毒清制剂安全性风险,特别是致肝功能异常风险,为临床合理用药提供参考。方法对我国药品不良反应监测系统数据库（2004年1月1日至2023年12月31日）、国内文献数据库（建库至2023年12月31日）中的湿毒清制剂肝损伤相关不良反应/事件进行整理与分析。结果国家药品不良反应监测系统数据库共收到涉及湿毒清制剂肝胆损害相关不良反应/事件病例报告24例;临床研究文献未见肝胆损害相关不良反应;个例报道涉及的不良反应/事件表现为药物性肝病、肝损伤。结论临床使用湿毒清制剂应关注肝损伤风险,提高安全合理用药意识,加强用药监测。同时,药品上市许可持有人应加强药物警戒及风险管理,做好用药指导与宣传,切实保障患者用药安全。

关键词: 湿毒清, 白鲜皮, 肝损伤, 中草药, 不良反应, 安全性, 风险

Abstract: Objective To analyze the risks of liver injury posed by Shiduqing preparations and provide reference for proper clinical use. Methods Literature about adverse reactions related to Shiduqing preparations in China’s adverse drug reaction monitoring database (collected between 2004 and 2023) and domestic database (from inception to December 31, 2023) was sorted out and analyzed. Results The National Adverse Drug Reaction Monitoring System Database documented 24 cases of adverse reactions related to liver and gallbladder damage and involving Shiduqing preparations. No adverse reactions related to hepatobiliary damage were found in clinical studies. The adverse reactions mentioned in individual reports were drug induced liver disease and liver injury. Conclusion Clinicians should be alert to the risk of liver injury when Shiduqing preparations are used in clinic. The awareness of safe and proper medications should be raised, and medications monitored. At the same time, drug marketing authorization holders should strengthen pharmacovigilance and provide guidance to ensure safe medication.

Key words: Shiduqing, Cortex Dictamni, liver injury, Chinese patent drug, adverse reaction, safety, risk

中图分类号:

R994.11
R986

邵波, 徐丽丽, 朱兰, 刘硕, 万浩, 黄光瑞. 湿毒清制剂肝损伤风险分析及思考[J]. 中国药物警戒, 2024, 21(6): 666-670.

SHAO Bo, XU Lili, ZHU Lan, LIU Shuo, WAN Hao, HUANG Guangrui. Risks of liver injury caused by Shiduqing preparations[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 666-670.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240137

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I6/666

参考文献

[1] NMPA. Announcement of the NMPA on Revising the Instructions of Shiduqing Preparations [EB/OL].(2021-01-19)[2024-04-01]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypshmshxdgg/20210119105826125.html.
[2] MA SW, LIU CH, LIU XY, et al.Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)[J]. Chinese Journal of Gastroenterol(胃肠病学), 2022, 27(6): 341-375.
[3] XIONG DZ, CHEN HQ, ZHAO M.Effect of fire needle acupoint therapy combined with Shiduqing capsule and paeonol ointment on the treatment of blood deficiency wind-dryness type eczema and its effect on the minimum erythema amount and the level of transforming growth Factor-β₁ in patients[J]. China’s Naturopathy(中国民间疗法), 2023, 31(4): 63-66.
[4] QIU JL, LI W, WU YG, et al.Effects of Shiduqing and Levocetirizine on inflammatory factor and therapeutic effects in elderly patients with diabetic pruritus[J]. Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine(中国中西医结合皮肤性病学杂志), 2020, 19(4): 342-345.
[5] LIN WJ, LIN YQ, LIN HW.Observation on the clinical effect of Shiduqing combined with ebastine in the treatment of atopic dermatitis[J]. Guangming Journal of Chinese Medicine(光明中医), 2017, 32(15): 2232-2234.
[6] BI JR.Evaluation of the efficacy and safety of Shiduqing capsule in the treatment of diabetic skin pruritus[J]. Diabetes New World(糖尿病新世界) , 2015, 35(4): 43.
[7] XIE M, SHA W, CUI QM.Clinical observation on enoxacin combined with Shiduqing capsules for preventing infection after bladder wall flap ureteroplasty on 40 cases[J]. China Pharmaceuticals(中国药业), 2014, 23(16): 114-115.
[8] YAO ZY, WANG C, YOU LP, et al.Clinical observation on the treatment of diabetic skin pruritus with Shiduqing[J]. Journal of Clinical Dermatology(临床皮肤科杂志), 2008, 37(12): 808.
[9] PAN WH, ZHENG J, ZHANG W, et al.Observation of multi-center effect of Shiduqing capsule on skin pruritus[J]. Journal of Clinical Dermatology(临床皮肤科杂志), 2008, 37(12): 811-812.
[10] GAO G.35 cases of chronic urticaria treated by loratadine combined with Shiduqing capsule umbilical seal therapy[J]. Jilin Medical Journal(吉林医学), 2008, 29(7): 587-588.
[11] YANG DQ, JIANG XN, BAI YP.Clinical study of blood insufficiency and wind dryness type of senile pruritus treated Byshiduqing capsule together with benzhydramine[J]. Beijing Journal of Traditional Chinese Medicine(北京中医药), 2008, 27(11): 866-868.
[12] HAO LY, LI ZC, WANG LH.Liver injury caused by Shiduqing capsules[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2020, 22(7): 420-421.
[13] HUANG L, LUO SP.One case of severe liver injury induced by Shiduqing tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(8): 511-512.
[14] ZHAO YL, MA XL.1 case of drug-induced liver disease caused by Shiduqing tablets[J]. For all Health(大家健康学术版), 2015, 9(17): 271-272.
[15] ZHANG XJ, YU SWQ.Research progress on the chemical constituents and pharmacological effects of Radix Sophorae Flavescentis[J]. Information on Traditional Chinese Medicine(中医药信息), 2023, 40(12): 79-87.
[16] MA XN, YANG SQ, ZHANG JC, et al.Research progress on pharmacological action of Kushen(Sophorae Flavescentis Radix)[J]. Journal of Liaoning University of Traditional Chinese Medicine(辽宁中医药大学学报), 2023, 25(1): 152-156.
[17] HUANG YX, GUO YM, ZHOU YF, et al.Dictamni cortex powder-induced liver injury based on integrated evidence chain[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2017, 42(3): 600-606.
[18] XIONG P, CHEN SS, SONG D, et al.Clinical cases and experimental evaluation of liver injury related to anti-psoriasis Keyin pills[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(20): 5017-5023.
[19] SHI W.Idiosyncratic hepatotoxicity evaluation and mechanism of Cortex Dictamni based on immune stress[D]. Nanchang: Jiangxi University of Chinese Medicine, 2020.
[20] WU KL.The hepatic protein adduction derived from reactive metabolites of multiple furanoids in Cortex Dictamni[D]. Zunyi: Zunyi Medicine University, 2022.
[21] NIU LN, WANG CG, JING L. Study on microbial-lipid metabolism mechanism of liver injury in wistar rats caused by Cortex Dictamni-Sophora Flavescens[J/OL]. (2024-01-08)[2024-04-11]. https://doi.org/10.13422/j.cnki.syfjx.20240424.
[22] FAN QY, ZHAO BS, ZHANG JX, et al.Analysis on drug factors for hepatotoxicity of Zhixue capsule[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2018, 24(1): 150-157.
[23] XIAO XH, TANG JY, MAO YM, et al.Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine[J]. Acta Pharmaceutica Sinica(药学学报), 2018, 53(11): 1931-1942.
[24] LYU DX, ZHANG F, QIN JQ, et al.Current status and advance of diagnosis of herb-induced liver injury[J]. Chinese Traditional and Herbal Drugs(中草药), 2024, 55(5): 1761-1769.

湿毒清制剂肝损伤风险分析及思考

Risks of liver injury caused by Shiduqing preparations

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	郭愿生, 左甜甜, 刘丽娜, 魏锋, 董喆, 李静, 金红宇, 马双成. 电感耦合等离子体质谱法测定麸炒薏苡仁中28种元素其风险评估[J]. 中国药物警戒, 2024, 21(9): 1008-1013.
[2]	路振凯, 杨顶权, 谢振年, 王连心, 黎元元, 王志飞, 崔鑫, 谢雁鸣. 《外用中成药临床应用药物警戒指南》解读与启示[J]. 中国药物警戒, 2024, 21(9): 1029-1033.
[3]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[4]	林璐, 詹陆川, 刘晓琦, 刘菊娥, 王来友, 曾颖, 赖伟华. 基于中国医院药物警戒系统建立地高辛不良事件主动监测电子触发器[J]. 中国药物警戒, 2024, 21(9): 1039-1043.
[5]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[6]	严妍, 刘乃一, 乔玲, 张毅, 杨晨. 别嘌醇片诱导的超敏反应综合征致暴发性1型糖尿病1例分析[J]. 中国药物警戒, 2024, 21(9): 1068-1070.
[7]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[8]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[9]	郑丽, 张凯华, 孙雪林. 小细胞肺癌治疗新药Tarlatamab药理作用及临床评价[J]. 中国药物警戒, 2024, 21(9): 1078-1080.
[10]	王岩, 滕晶晶, 杨同金, 夏新, 喻丹丹, 占海兵, 杨文明. 智脑胶囊长期毒性研究[J]. 中国药物警戒, 2024, 21(8): 878-883.
[11]	孙一鑫, 聂晓璐, 王晓玲, 郭鹏. 国内外基于真实世界数据的药品上市后安全性主动监测系统对比分析[J]. 中国药物警戒, 2024, 21(8): 892-899.
[12]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[13]	刘倩, 李博, 疏欣扬. 蓝芩口服液联合抗菌药物治疗急性扁桃体炎有效性与安全性的系统评价与Meta分析[J]. 中国药物警戒, 2024, 21(8): 916-920.
[14]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[15]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.